

## SEQUENCE LISTING

<110> Vajnik, Vandanna  
Samuels, Herbert  
Li, Dangsheng

<120> NRIF3, A Novel Co-Activator for Nuclear  
Hormone Receptors

<130> 5986/1G098-US1

<140> TBA

<141> Concurrently Herewith

<150> US 60/154,347

<151> 1999-09-17

<160> 10

<170> FastSEQ for Windows Version 3.0

<210> 1

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<221> UNSURE

<222> (2)...(3)

<223> Conserved motif for SRC-1 and CBP/p300 with  
nuclear receptors;  
Xaa represents any amino acid

<400> 1

Leu Xaa Xaa Leu Leu  
1 5

<210> 2

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<221> UNSURE

<222> (2)...(3)

<223> Domain of NRIF3 that interacts with liganded  
receptors;  
Xaa represents any amino acid

<400> 2

Leu Xaa Xaa Ile Leu  
1 5

<210> 3  
 <211> 592  
 <212> DNA  
 <213> Homo Sapien

<400> 3

|             |            |            |             |            |            |     |
|-------------|------------|------------|-------------|------------|------------|-----|
| cagcggcagt  | ggtgctttcc | cgaatctcag | aatgcctggt  | aaaagatcac | tgaagttgga | 60  |
| tggtctgtta  | gaagaaaatt | catttgatcc | ttcaaaaatc  | aaggaagaaa | gtgttataac | 120 |
| ttattctcca  | acaactggaa | cttgtcaaat | gagtcctattt | gcttctccca | caagttctga | 180 |
| agagcaaaaag | cacagaaatg | gactatcaaa | tgaaaagaga  | aaaaaattga | atcacccagt | 240 |
| ttaactgaaa  | gcaaagaatc | tacaacaaaa | gacaatgatg  | aattcatgat | gttgctatca | 300 |
| aaagttgaga  | aattgtcaga | agaaatcatg | gagataatgc  | aaaatttaag | tagtatacag | 360 |
| gctttggagg  | gcagtagaga | gcttgaaaat | ctcattggaa  | tctcctgtgc | atcacatttc | 420 |
| taaaaagaga  | aatgcagaaa | accaaagaac | taatgacaaa  | gtgaataaac | aaaactgttt | 480 |
| gaaaagagta  | caggacttcc | tcacaaagca | tcacgtcatc  | ttgacagcta | tgaattcctt | 540 |
| aaagcatttt  | aaactgaggc | attaagaaga | aatgcactca  | ccatgagcac | ca         | 592 |

<210> 4  
 <211> 177  
 <212> PRT  
 <213> Homo Sapien

<400> 4

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Met | Pro | Val | Lys | Arg | Ser | Leu | Lys | Leu | Asp | Gly | Leu | Leu | Glu | Glu | Asn |
| 1   |     |     | 5   |     |     |     |     |     | 10  |     |     |     |     | 15  |     |
| Ser | Phe | Asp | Pro | Ser | Lys | Ile | Thr | Arg | Lys | Lys | Ser | Val | Ile | Thr | Tyr |
|     |     |     | 20  |     |     |     |     | 25  |     |     |     |     | 30  |     |     |
| Ser | Pro | Thr | Thr | Gly | Thr | Cys | Gln | Met | Ser | Leu | Phe | Ala | Ser | Pro | Thr |
|     |     |     | 35  |     |     |     | 40  |     |     |     |     | 45  |     |     |     |
| Ser | Ser | Glu | Glu | Gln | Lys | His | Arg | Asn | Gly | Leu | Ser | Asn | Glu | Lys | Arg |
|     |     |     | 50  |     |     | 55  |     |     |     |     | 60  |     |     |     |     |
| Lys | Lys | Leu | Asn | His | Pro | Ser | Leu | Thr | Glu | Ser | Lys | Glu | Ser | Thr | Thr |
|     |     |     |     |     | 70  |     |     |     | 75  |     |     |     |     | 80  |     |
| Lys | Asp | Asn | Asp | Glu | Phe | Met | Met | Leu | Leu | Ser | Lys | Val | Glu | Lys | Leu |
|     |     |     |     | 85  |     |     |     | 90  |     |     |     |     | 95  |     |     |
| Ser | Glu | Glu | Ile | Met | Glu | Ile | Met | Gln | Asn | Leu | Ser | Ser | Ile | Gln | Ala |
|     |     |     | 100 |     |     |     |     | 105 |     |     |     |     | 110 |     |     |
| Leu | Glu | Gly | Ser | Arg | Glu | Leu | Glu | Asn | Leu | Ile | Gly | Ile | Ser | Cys | Ala |
|     |     |     | 115 |     |     |     | 120 |     |     |     |     | 125 |     |     |     |
| Ser | His | Phe | Leu | Lys | Arg | Glu | Met | Gln | Lys | Thr | Lys | Glu | Leu | Met | Thr |
|     |     |     | 130 |     |     | 135 |     |     |     |     | 140 |     |     |     |     |
| Lys | Val | Asn | Lys | Gln | Lys | Leu | Phe | Glu | Lys | Ser | Thr | Gly | Leu | Pro | His |
|     |     |     |     |     | 150 |     |     |     | 155 |     |     |     |     | 160 |     |
| Lys | Ala | Ser | Arg | His | Leu | Asp | Ser | Tyr | Glu | Phe | Leu | Lys | Ala | Ile | Leu |
|     |     |     | 165 |     |     |     |     | 170 |     |     |     |     |     | 175 |     |
| Asn |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |

<210> 5  
 <211> 4  
 <212> PRT  
 <213> Artificial Sequence

<220>

<223> Nuclear localization sequence of NRIF3

<400> 5

Lys Arg Lys Lys

1

<210> 6

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> C-terminus of beta3-endotoxin long form protein

<400> 6

Gly Gln Pro Gln Met Ser Pro Gln Leu

1

5

<210> 7

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> C-terminal peptide of NRIF3

<400> 7

Lys Ala Ser Arg His Leu Asp Ser Tyr Glu Phe Leu Lys Ala Ile Leu

1

5

10

15

Asn

<210> 8

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> 20-residue peptide of the second LxxLL box of SRC-1

<400> 8

Ser Leu Thr Glu Arg His Lys Ile Leu His Arg Leu Leu Gln Glu Gly

1

5

10

15

Ser Pro Ser Asp

20

<210> 9

<211> 12

<212> DNA

<213> Artificial Sequence

<220>

<223> Idealized inverted repeat

